April 16, 2014 12:08 PM ET

Healthcare Providers and Services

Company Overview of RedPath Integrated Pathology, Inc.

Company Overview

RedPath Integrated Pathology, Inc., a genomics-based cancer diagnostic company, provides molecular analysis to resolve diagnostic dilemmas. The company offers PathFinderTG, a molecular analysis of mutations in genomic DNA for cases where traditional pathology results in an indeterminate, suspicious, or a typical diagnosis. Its PathFinderTG differentiates metastatic, synchronous, and recurrent tumors in various organs, such as breast, lungs, liver, endometrium, and ovaries. The company’s PathFinderTG analysis is validated in pancreas, esophagus, biliary ducts, and brain. It serves pathologists, oncologists, clinicians, and patients. RedPath Integrated Pathology, Inc. was founded in 2004 and i...

2515 Liberty Avenue

Pittsburgh, PA 15222

United States

Founded in 2004





Key Executives for RedPath Integrated Pathology, Inc.

Chief Executive Officer and Director
Age: 61
Founder and Chief Scientific Officer
Vice President of Reimbursement and Payor Relations
Director of Sales & Marketing
Vice President of Sales and Reimbursement
Compensation as of Fiscal Year 2013.

RedPath Integrated Pathology, Inc. Key Developments

RedPath Integrated Pathology, Inc. Launches Accucea Chemistry Test for Pancreatic Cyst Patients

RedPath Integrated Pathology, Inc. announced the launch of a new, patent-pending, customized test to accurately measure carcinoembryonic antigen in all pancreatic cyst fluids. Unlike routinely used, commercially available CEA assays, AccuCEA(TM) provides accurate results, even in pancreatic cyst fluid specimens with limited volume and/or high viscosity. Furthermore, AccuCEA provides physicians with more options in the diagnostic work-up of patients by preserving precious fluid and making it available for additional tests. When the amount of pancreatic cyst fluid is limited and CEA testing is prescribed, CEA can be analyzed in diluted fluid. However, dilution of cyst fluid can significantly impact the analytical accuracy of the resulting CEA measurements. RedPath has solved this problem by creating AccuCEA, which provides CEA measurements in diluted cyst fluid that are true to their corresponding neat (undiluted) cyst fluid CEA measurements. Results of the study documenting the accuracy of AccuCEA were presented at the 2013 Digestive Disease Week meeting.

RedPath Integrated Pathology, Inc. Presents at 25th Annual Piper Jaffray Healthcare Conference 2013, Dec-03-2013 04:30 PM

RedPath Integrated Pathology, Inc. Presents at 25th Annual Piper Jaffray Healthcare Conference 2013, Dec-03-2013 04:30 PM. Venue: The New York Palace Hotel, 455 Madison Avenue, New York, NY 10022, United States. Speakers: Dennis Morgan Smith, Chief Executive Officer and Director.

Similar Private Companies By Industry

Company Name Region
Rebecca's House United States
Metropolitan Health Care, Inc. United States
Stratford 360 United States
Southern Maine Health Care United States
Sunrise VA Medical, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RedPath Integrated Pathology, Inc., please visit www.redpathip.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.